FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3148142168> ?p ?o ?g. }

• W3148142168 abstract "Deregulation of fibroblast growth factor receptors (FGFRs) signaling, as a result of FGFR amplification, chromosomal translocation, or mutations, is involved in both initiation and progression of a wide range of human cancers. Clinical data demonstrating the dependence of cancer cells on FGFRs signaling clearly indicate these receptors as the molecular targets of anti-cancer therapies. Despite the increasing number of tyrosine kinase inhibitors (TKIs) being investigated in clinical trials, acquired resistance to these drugs poses a serious therapeutic problem. In this study, we focused on a novel pan-FGFR inhibitor—CPL304110, currently being investigated in phase I clinical trials in adults with advanced solid malignancies. We analyzed the sensitivity of 17 cell lines derived from cancers with aberrant FGFR signaling, i.e. non-small cell lung cancer, gastric and bladder cancer to CPL304110. In order to explore the mechanism of acquired resistance to this FGFR inhibitor, we developed from sensitive cell lines their variants resistant to CPL304110. Herein, for the first time we revealed that the process of acquired resistance to the novel FGFR inhibitor was associated with increased expression of MET in lung, gastric, and bladder cancer cells. Overexpression of MET in NCI-H1703, SNU-16, RT-112 cells as well as treatment with HGF resulted in the impaired response to inhibition of FGFR activity. Moreover, we demonstrated that cells with acquired resistance to FGFR inhibitor as well as cells overexpressing MET displayed enhanced migratory abilities what was accompanied with increased levels of Pyk2 expression. Importantly, inhibition of both MET and Pyk2 activity restored sensitivity to FGFR inhibition in these cells. Our results demonstrate that the HGF/MET-Pyk2 signaling axis confers resistance to the novel FGFR inhibitor, and this mechanism is common for lung, gastric, and bladder cancer cells. Our study suggests that targeting of MET/Pyk2 could be an approach to overcome resistance to FGFR inhibition." @default.
• W3148142168 created "2021-04-13" @default.
• W3148142168 creator A5014283206 @default.
• W3148142168 creator A5025303490 @default.
• W3148142168 creator A5043905816 @default.
• W3148142168 creator A5045102648 @default.
• W3148142168 creator A5050224198 @default.
• W3148142168 creator A5066835672 @default.
• W3148142168 creator A5072107481 @default.
• W3148142168 creator A5074594600 @default.
• W3148142168 creator A5076479884 @default.
• W3148142168 creator A5085628749 @default.
• W3148142168 creator A5090065776 @default.
• W3148142168 date "2021-04-07" @default.
• W3148142168 modified "2023-10-06" @default.
• W3148142168 title "MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells" @default.
• W3148142168 cites W1499045271 @default.
• W3148142168 cites W1563019250 @default.
• W3148142168 cites W1960850967 @default.
• W3148142168 cites W1965022745 @default.
• W3148142168 cites W1971382968 @default.
• W3148142168 cites W1988476050 @default.
• W3148142168 cites W1992142919 @default.
• W3148142168 cites W1995168697 @default.
• W3148142168 cites W1996645442 @default.
• W3148142168 cites W2005519312 @default.
• W3148142168 cites W2005792607 @default.
• W3148142168 cites W2014689880 @default.
• W3148142168 cites W2017578325 @default.
• W3148142168 cites W2031541885 @default.
• W3148142168 cites W2044293524 @default.
• W3148142168 cites W2049086297 @default.
• W3148142168 cites W2051676407 @default.
• W3148142168 cites W2054195724 @default.
• W3148142168 cites W2055560819 @default.
• W3148142168 cites W2064466084 @default.
• W3148142168 cites W2066141186 @default.
• W3148142168 cites W2070483380 @default.
• W3148142168 cites W2082361648 @default.
• W3148142168 cites W2095605190 @default.
• W3148142168 cites W2098320019 @default.
• W3148142168 cites W2098466520 @default.
• W3148142168 cites W2100374586 @default.
• W3148142168 cites W2105020329 @default.
• W3148142168 cites W2107342944 @default.
• W3148142168 cites W2113235293 @default.
• W3148142168 cites W2125921134 @default.
• W3148142168 cites W2125964443 @default.
• W3148142168 cites W2127385754 @default.
• W3148142168 cites W2138173746 @default.
• W3148142168 cites W2141298701 @default.
• W3148142168 cites W2144747113 @default.
• W3148142168 cites W2146094598 @default.
• W3148142168 cites W2151044814 @default.
• W3148142168 cites W2153089464 @default.
• W3148142168 cites W2159060826 @default.
• W3148142168 cites W2160407216 @default.
• W3148142168 cites W2180330327 @default.
• W3148142168 cites W2498183210 @default.
• W3148142168 cites W2544538072 @default.
• W3148142168 cites W2550856922 @default.
• W3148142168 cites W2595713273 @default.
• W3148142168 cites W2626344037 @default.
• W3148142168 cites W2683235845 @default.
• W3148142168 cites W2752178836 @default.
• W3148142168 cites W2752422982 @default.
• W3148142168 cites W2758683424 @default.
• W3148142168 cites W2763874653 @default.
• W3148142168 cites W2795945766 @default.
• W3148142168 cites W2884026813 @default.
• W3148142168 cites W2891107228 @default.
• W3148142168 cites W2899266085 @default.
• W3148142168 cites W2900521824 @default.
• W3148142168 cites W2907315680 @default.
• W3148142168 cites W2952892955 @default.
• W3148142168 cites W2969349514 @default.
• W3148142168 cites W3007750009 @default.
• W3148142168 cites W3032673000 @default.
• W3148142168 cites W3097439385 @default.
• W3148142168 doi "https://doi.org/10.3389/fonc.2021.633410" @default.
• W3148142168 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8059549" @default.
• W3148142168 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33898310" @default.
• W3148142168 hasPublicationYear "2021" @default.
• W3148142168 type Work @default.
• W3148142168 sameAs 3148142168 @default.
• W3148142168 citedByCount "5" @default.
• W3148142168 countsByYear W31481421682021 @default.
• W3148142168 countsByYear W31481421682022 @default.
• W3148142168 countsByYear W31481421682023 @default.
• W3148142168 crossrefType "journal-article" @default.
• W3148142168 hasAuthorship W3148142168A5014283206 @default.
• W3148142168 hasAuthorship W3148142168A5025303490 @default.
• W3148142168 hasAuthorship W3148142168A5043905816 @default.
• W3148142168 hasAuthorship W3148142168A5045102648 @default.
• W3148142168 hasAuthorship W3148142168A5050224198 @default.
• W3148142168 hasAuthorship W3148142168A5066835672 @default.
• W3148142168 hasAuthorship W3148142168A5072107481 @default.
• W3148142168 hasAuthorship W3148142168A5074594600 @default.
• W3148142168 hasAuthorship W3148142168A5076479884 @default.
• W3148142168 hasAuthorship W3148142168A5085628749 @default.

• next